LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.11
New Release Features showcasing of gene-relevant scientific
ALAMEDA, Calif.--(BUSINESS WIRE)--Dec. 6, 2013--
LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX),
announced today the release of GeneCards®, Version
3.11. The new release is available at www.genecards.org.
GeneCards® is a comprehensive online database that
provides comprehensive information on all human genes. It is accessed by
professionals in many institutions including academia, research
hospitals, patent offices, and leading biotech and pharma companies.
LifeMap Sciences holds the exclusive worldwide license to market GeneCards®
from Yeda Research and Development Company Ltd., the commercial arm of
the Weizmann Institute of Science.
GeneCards® 3.11 now showcases gene-related scientific
conferences, including links to ESCMID 2014 on Microbiology & Infectious
Diseases, AD/PD 2014 on Alzheimer’s and Parkinson’s disease and ISPPD-9
on Pneumococci and Pneumococcal diseases.
Additional features of the new GeneCards® release
More than 122,000 gene entries, including the world’s largest arsenal
of ~77,000 non-protein-coding RNAs.
Revamped comprehensive version of the popular disease-gene list with
links to MalaCards (www.malacards.org),
our Human Disease Compendium.
Enhanced information about genetic variations and disease mutations
Gene classifications from HGNC and IUPHAR
Information on protein-binding ligands from the International Union of
Basic and Clinical Pharmacology (IUPHAR)
Enhanced proteomics section with new tissue expression data from the
Improved presentation of expression in embryonic tissues from LifeMap
and new antibodies.
“It is a pleasure to see GeneCards making new progress in its mission to
cover ‘all about human genes’. I am especially proud to see the new
information from the International Union of Basic and Clinical
Pharmacology, covering both gene-related binding molecules (ligands) and
protein classification. Along with our newly enhanced super-pathways and
novel proteome data, these items portray the inventiveness of our
academic team,” said Professor Doron Lancet, Ph.D., The Ralph D. and
Lois R. Silver Professor of Human Genomics, at the Weizmann Institute of
“We continue focusing on making GeneCards® a go-to
platform for the biomedical research community, and are looking to
expand our offerings of gene-related scientific conferences through
future collaborations,” stated Yaron Guan-Golan, Chief Marketing Officer
of LifeMap Sciences.
About LifeMap Sciences, Inc.
LifeMap Sciences’ (www.lifemapsc.com)
core technology and business is based on its Integrated Biomedical
Knowledgebase and discovery platform for biomedical research, which
currently includes GeneCards®:
the leading human gene database; LifeMap
Discovery™, the database of embryonic development, stem cell
research and regenerative medicine; and MalaCards,
the human disease database. LifeMap’s products are used in many
institutions including academia, research hospitals, patent offices, and
leading biotechnology and pharmaceutical companies. LifeMap is also
engaged in therapeutics discovery, utilizing LifeMap’s proprietary
platform to aid in the development of products for the treatment of
degenerative diseases, including utilizing BioTime’s proprietary, PureStem™
human progenitor cell lines. In addition to its currently marketed
products, LifeMap is pursuing several new internet and informatics
products with substantial rapid revenue growth potential, leveraging its
existing products and their large user base.
About BioTime, Inc.
BioTime is a biotechnology company engaged in research and product
development in the field of regenerative medicine. Regenerative medicine
refers to therapies based on stem cell technology that are designed to
rebuild cell and tissue function lost due to degenerative disease or
injury. BioTime’s focus is on pluripotent stem cell technology based on
human embryonic stem (“hES”) cells and induced pluripotent stem (“iPS”)
cells. hES and iPS cells provide a means of manufacturing every cell
type in the human body and therefore show considerable promise for the
development of a number of new therapeutic products. BioTime’s
therapeutic and research products include a wide array of proprietary PureStem™
progenitors, HyStem® hydrogels, culture media, and
differentiation kits. BioTime is developing Renevia™ (a HyStem®
product) as a biocompatible, implantable hyaluronan and collagen-based
matrix for cell delivery in human clinical applications. In addition,
BioTime has developed Hextend®, a blood
plasma volume expander for use in surgery, emergency trauma treatment
and other applications. Hextend® is manufactured and
distributed in the U.S. by Hospira, Inc. and in South Korea by CJ
CheilJedang Corporation under exclusive licensing agreements.
BioTime is also developing stem cell and other products for research,
therapeutic, and diagnostic use through its subsidiaries:
OncoCyte Corporation is developing products and technologies to
diagnose and treat cancer.
ES Cell International Pte Ltd., a Singapore private limited company,
develops hES products for research use.
OrthoCyte Corporation is developing therapies to treat orthopedic
disorders, diseases and injuries.
ReCyte Therapeutics, Inc. is developing therapies to treat a variety
of blood and lymphatic vascular disorders, as well as products for
research using iPS and other cell reprogramming technology.
Cell Cure Neurosciences Ltd. is an Israel-based biotechnology company
focused on developing stem cell-based therapies for retinal and
neurological degenerative diseases. Its lead product is OpRegen®
for the treatment of macular degeneration.
LifeMap Sciences, Inc. markets, sells and distributes GeneCards®,
the leading human gene database, as part of an integrated database
suite that also includes the LifeMap Discovery™ database of
embryonic development, stem cell research and regenerative medicine,
and MalaCards, the human disease database.
Asterias Biotherapeutics, Inc. is a newly formed subsidiary whose
first acquisition was the stem cell assets of Geron Corporation,
including patents and other intellectual property, biological
materials, reagents and equipment for the development of new
therapeutic products for regenerative medicine.
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
About the Weizmann Institute of Science and GeneCards
The Weizmann Institute of Science in Rehovot, Israel, is one of the
world's top-ranking multidisciplinary research institutions. Noted for
its wide-ranging exploration of the natural and exact sciences, the
Institute is home to scientists, postdoctoral fellows, Ph.D. and M.Sc.
students, and scientific, technical and administrative staff. In
addition, visiting scientists and their families – over 500 from 35
countries are regularly hosted at the Institute. The Institute was
founded in 1934 following a donation to Dr. Chaim Weizmann, a noted
biochemist and biotechnologist, who envisioned the establishment of a
world-class scientific research center in Israel, and later also became
the first President of the State of Israel. Weizmann Institute’s
Feinberg Graduate School,established in 1958, has 1000 M.Sc. and Ph.D.
students enrolled in studies covering the Institute’s five faculties:
Biochemistry, Biology, Chemistry, Physics, and Mathematics and Computer
Science. The Institute’s technology transfer arm, Yeda Research and
Development Co. was the first company of its kind in Israel, and is
currently one of the most successful worldwide. Institute research
efforts include the search for new ways of fighting disease and hunger,
examining leading questions in mathematics and computer science, probing
the physics of matter and the universe, creating novel materials and
developing new strategies for protecting the environment. Particular
excellence in bioinformatics and systems biology is manifested, among
others, in the GeneCards project, initiated in 1996, under the
leadership of Prof. Doron Lancet of the Dept. of Molecular Genetics,
Head of the Crown Human Genome Center. A team of 10 led by Marilyn
Safran continuously innovates and keeps GeneCards as a world-top human
gene compendium, automatically mining and integrating 100 worldwide web
Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development, and
potential opportunities for BioTime and its subsidiaries, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates”) should also be
considered to be forward-looking statements. Forward-looking statements
involve risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or regulatory
approvals, need and ability to obtain future capital, and maintenance of
intellectual property rights. Actual results may differ materially from
the results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that affect the
business of BioTime and its subsidiaries, particularly those mentioned
in the cautionary statements found in BioTime's Securities and Exchange
Commission filings. BioTime disclaims any intent or obligation to update
these forward-looking statements.
Source: BioTime, Inc.
Lesley Stolz, 510-521-3390 ext. 367
Vice President Corporate Development
Segall, 510-521-3390 ext. 301
Kenneth Elsner, 781-826-7719